Fennec Pharmaceuticals Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the first quarter 2026 to a ratio of 2.59, this is below the company average, and notable indication of worsening business environment. Average receivable collection period, for the Fennec Pharmaceuticals Inc in Mar 31 2026 quarter, has decreased to 141 days, compared to 155 days, in the Dec 31 2025 quarter.

If we take a look into Healthcare sector 448 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 2663, from overall ranking in the fourth quarter 2025 at 2706.

What is Receivable Turnover Ratio?
What is Fennec Pharmaceuticals Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

FENC Receivables Turnover Ratio	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Receivable Change	21.45 %	80.23 %	49.85 %	42.15 %	50.36 %
Y / Y Revenue Change	72.64 %	73.84 %	78.69 %	32.91 %	-65.52 %
Receivable Turnover Ratio (TTM)	2.59	2.36	2.38	2.27	2.31
FENC's Total Ranking	# 2663	# 2706	# 0	# 0	# 0
Accounts Receivable average collection period days	141	154	153	161	158
Seq. Receivable Change	-19.2 %	20.05 %	10.52 %	13.3 %	19.9 %
Seq. Revenue Change	9.66 %	10.55 %	29.11 %	10.3 %	10.42 %

Receivable Turnover Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 52
Healthcare Sector	# 449
Overall Market	# 2663

Receivable Turnover Ratio Statistics
High	Average	Low
5.12	3.36	2.36
(Sep 30 2023)		(Dec 31 2025)

FENC Company Profile • Back to FENC Efficiency Comparisons • Compare FENC Receivables Turnover Ratio to its Competitors

Financial Statements
Fennec Pharmaceuticals Inc 's Accounts Receivable	$ 19 Millions	Visit FENC's Balance sheet
Fennec Pharmaceuticals Inc 's Sales TTM	$ 51 Millions	Visit FENC's Income Statement
Sources of FENC's Revenues		Visit FENC's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
FENC's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
FENC's Growth Rates	FENC's Roa	FENC's Inventory Turnover Ratio	FENC's Dividend Comparisons
FENC's Profitability Ratios	FENC's Roi	FENC's Asset Turnover Ratio	FENC's Dividend Growth
FENC's Valuation Ratios	FENC's Roe	FENC's Financial Strength Ratios	FENC's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Mar 31 2026	Receivable at quarter ending Mar 31 2026
Maravai Lifesciences Holdings Inc	7.46	$ 203.841 Millions	$ 27.333 Millions
Travere Therapeutics Inc	7.42	$ 536.195 Millions	$ 72.285 Millions
Lemaitre Vascular Inc	7.42	$ 256.515 Millions	$ 34.583 Millions
Twist Bioscience Corporation	7.41	$ 409.479 Millions	$ 55.272 Millions
Quidelortho Corp	7.39	$ 2,657.200 Millions	$ 359.600 Millions
Koru Medical Systems Inc	7.38	$ 43.257 Millions	$ 5.863 Millions
Si bone inc	7.38	$ 206.128 Millions	$ 27.945 Millions
Avita Medical Inc	7.36	$ 72.347 Millions	$ 9.832 Millions
Nephros Inc	7.32	$ 19.464 Millions	$ 2.659 Millions
Aurinia Pharmaceuticals Inc	7.30	$ 298.295 Millions	$ 40.837 Millions
Rhythm Pharmaceuticals Inc	7.27	$ 217.165 Millions	$ 29.857 Millions
Castle Biosciences Inc	7.25	$ 339.920 Millions	$ 46.860 Millions
10x Genomics Inc	7.20	$ 637.614 Millions	$ 88.572 Millions
Star Equity Holdings Inc	7.17	$ 209.296 Millions	$ 29.202 Millions
Angiodynamics Inc	7.16	$ 311.277 Millions	$ 43.494 Millions
Universal Health Services Inc	7.15	$ 18,292.509 Millions	$ 2,558.777 Millions
Verastem Inc	7.14	$ 49.585 Millions	$ 6.941 Millions
Cerus Corporation	7.14	$ 215.758 Millions	$ 30.216 Millions
Iridex Corp	7.12	$ 51.160 Millions	$ 7.182 Millions
Boston Scientific Corporation	7.11	$ 20,616.000 Millions	$ 2,899.000 Millions
Hca Healthcare Inc	7.09	$ 76,388.000 Millions	$ 10,769.500 Millions
Lifecore Biomedical Inc	7.07	$ 125.080 Millions	$ 17.691 Millions
Transmedics Group Inc	7.05	$ 635.890 Millions	$ 90.141 Millions
Arvinas Inc	7.05	$ 89.400 Millions	$ 12.675 Millions
Enhabit Inc	7.03	$ 1,064.900 Millions	$ 151.400 Millions
Biogen Inc	6.96	$ 9,937.400 Millions	$ 1,427.475 Millions
Tarsus Pharmaceuticals Inc	6.96	$ 589.621 Millions	$ 84.723 Millions
Beyond Air Inc	6.95	$ 6.065 Millions	$ 0.873 Millions
Insulet Corporation	6.93	$ 2,900.800 Millions	$ 418.625 Millions
Medpace Holdings Inc	6.92	$ 2,678.268 Millions	$ 386.904 Millions

Date modified: 2026-06-23T19:22:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.